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Impact of cord blood banking technologies on clinical outcome:
a Eurocord/Cord Blood Committee (CTIWP), European Society
for Blood and Marrow Transplantation and NetCord
retrospective analysis
Riccardo Saccardi,1,2 Luciana Tucunduva,2 Annalisa Ruggeri,2,3 Irina Ionescu,4 Gesine Koegler,5
Sergio Querol,6 Giuliano Grazzini,7 Lucilla Lecchi,8 Alessandro Nanni Costa,9 Cristina Navarrete,10
Fabienne Pouthiers,11 Jerome Larghero,12 Donna Regan,13 Taryn Freeman,14
Henrique Bittencourt,15 Chantal Kenzey,2 Myriam Labopin,3 Etienne Baudoux,16
Vanderson Rocha,2,17 and Eliane Gluckman2,18
BACKGROUND: Techniques for banking cord blood
units (CBUs) as source for hematopoietic stem cell
transplantation have been developed over the past 20
years, aimed to improve laboratory efficiency without
altering the biologic properties of the graft. A large-scale,
registry-based assessment of the impact of the banking
variables on the clinical outcome is currently missing.
STUDY DESIGN AND METHODS: A total of 677
single cord blood transplants (CBTs) carried out for acute
leukemia in complete remission in centers affiliated with
the European Society for Blood and Marrow
Transplantation were selected. An extensive set of data
concerning CBU banking were collected and correlations
with clinical outcome were assessed. Clinical endpoints
were transplant-related mortality, engraftment, and graft-
versus-host disease (GVHD).
RESULTS: The median time between collection and
CBTwas 4.1 years (range, 0.2-16.3 years). Volume
reduction (VR) of CBUs before freezing was performed in
59.2% of available reports; in half of these the frozen
volume was less than 30 mL. Cumulative incidences of
neutrophil engraftment on Day 60, 100-day acute GVHD
(II-IV), and 4-year chronic GVHD were 87, 29, and
216 2%. The cumulative incidence of nonrelapse
mortality (NRM) at 100 days and 4-year NRM were,
respectively, 166 2 and 306 2%. Neither the variables
related to banking procedures nor the interval between
collection and CBT influenced the clinical outcome.
CONCLUSION: These findings indicate a satisfactory
validation of the techniques associated with CBU VR
across the banks. Cell viability assessment varied among
the banks, suggesting that efforts to improve the
standardization of CBU quality controls are needed.
ABBREVIATIONS: ALL5 acute lymphoblastic leukemia; AML 5
acute myeloid leukemia; CB 5 cord blood; CBB(s) 5 cord
blood bank(s); CBT(s) 5 cord blood transplantation(s);
CBU(s) 5 cord blood unit(s); CR 5 complete remission;
CR1 5 first complete remission; CR2 5 second complete
remission; CR3 5 third complete remission; EBMT 5
European Society for Blood and Marrow Transplantation;
HR 5 hazard ratio; HSC(s) 5 hematopoietic stem cell(s);
LFS 5 leukemia-free survival; MAC 5 myeloablative
conditioning; NRM 5 nonrelapse mortality; OS 5 overall
survival; RI 5 relapse incidence; RIC 5 reduced-intensity
conditioning; TNC(s) 5 total nucleated cell(s).
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C
ord blood (CB) has been increasingly employed
over the past 20 years as a source of hematopoi-
etic stem cells (HSCs) for transplantation.1
Favorable initial results of related cord blood
transplantation (CBT), including a lower rate of acute and
chronic graft-versus-host disease (GVHD) when compared
to other sources of HSCs,2 led to the creation of unrelated
CB banks after 1992.3-5 Due to both the availability of a
large inventory of cord blood units (CBUs) and the
improvement of transplant technology, the number of
transplants using this source of stem cells increased sig-
nificantly (Eurocord, personal communication).
Collection of CB is usually performed in a maternity
unit linked to a cord blood bank (CBB). All other proce-
dures (characterization, processing, freezing, and storage
of the CBU) are performed at the bank. Thus, success of a
CBT is strongly dependent on the quality of the CBB activ-
ity.6,7 The definition of “high-quality units” is generally
referred to large-size units that contain a high number of
hematopoietic progenitors to ensure faster engraftment.
However, the concept of quality in CB banking generally
refers to the consistency of the CBU data reported by the
banks to the registries. Discrepancies between CBU data
reported by the bank and transplant center have been
reported, which could possibly affect the selection of the
most suitable CBU and therefore clinical outcomes.8 Such
discrepancies may also result from the variability of
manipulation and the CBU characterization practice after
thawing at transplant centers.9,10
Despite the development of CB banking standards
and accreditation programs, a large variability in labora-
tory techniques still exists, with special reference to CBU
characterization and volume reduction (VR). The latter
represents a major issue for any allogeneic CBB as the low
probability of a CBU being released results in a waste of
cryogenic space and operational costs.11 Techniques for
reducing the CBU volume while preserving the majority of
HSCs and their biologic properties result in a reduction of
the storage-associated costs. VR methods are usually
based on the centrifugation of the product and targeted to
either collect the leukoenriched layer between plasma and
red blood cells (RBCs; buffy coat) or to remove the
plasma. The frozen product is usually stored in liquid
nitrogen for years before clinical use. The different techni-
ques of VR significantly modify the physical characteris-
tics of the graft, such as the hematocrit and the total
nucleated cells (TNC) and polymorphonuclear cells
(PMNs) concentration, possibly modifying the viability of
HSCs after the freezing-thawing process. The impact of
VR technologies in the viability of HSC after thawing has
so far been reported by single institutions,12-14 but a large
retrospective, registry-based analysis of VR on clinical out-
come after CBT is still lacking. Indeed, other laboratory
variables can influence the CBT process, including storage
technology, the assessment of HSC content and, in partic-
ular, quality controls (QCs) upon release of the CBU.
The primary aim of this study was to retrospectively
analyze the impact of the major variables associated with
CB banking on the clinical outcome of an extensive set of
patients who have undergone a CBT. Data concerning 677
unrelated CBUs delivered for single CBT, carried out from
1997 to 2010 in centers affiliated to the European Society
for Blood and Marrow Transplantation (EBMT; www.
ebmt.org) and reported to the Eurocord Registry, were col-
lected from the banks that released the units. We report
here the analysis of the correlation between such data and
clinical endpoints.
MATERIALS AND METHODS
Study design
Major variables associated with the banking process, from
collection to release, were listed. Only single CBU trans-
plants were selected to avoid the overlapping of graft vari-
ables of multiple units. The inclusion criteria of transplant
recipients focused on variables related to the quality of
the banking process; therefore, patients with the same
diagnosis (acute leukemia) and disease status (complete
remission [CR]) at CBT were selected. TNC number at
freezing 33107 is associated with a better engraftment
rate and overall survival (OS)15,16 and therefore was
selected as the minimum threshold for inclusion in this
study. CBTs carried out between 1997 and 2010 were
included, so as to be able to provide an adequate follow-
up. Other cellular variables, such as CD341 cell count and
colony-forming units were not universally performed,
especially in the older units, and therefore they were not
considered mandatory data for inclusion in this study. A
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negative impact of the degree of HLA disparity was
reported on both engraftment and nonrelapse mortality
(NRM);17 however, in the single-unit transplant setting, a
disparity of not more than two of six HLA-A,B and DRB1
antigens is generally accepted.
Therefore, the selection criteria for this analysis
included patients with acute leukemias in any CR who
had undergone a single unmanipulated CBT from an
unrelated donor in EBMT centers. Further inclusion crite-
ria were TNC at cryopreservation of at least 3 3 107/kg and
HLA-A,B (HLA typing at antigen level) and DRB1 (HLA
typing at allele level) disparity of not more than two of
six. Patients were classified as pediatric when their age
was not more than 18 years. A minimum data set was
also considered mandatory for inclusion in the study,
such as follow-up with complete outcome data and bank
identification.
Banking variables
Most banks did not concentrate the CBUs at the begin-
ning of their activity and this started at a later stage; others
began using one method and then switched to another.
Indeed, concentration may well have been started with a
manual method and subsequently carried out with an
automated method. Therefore, we focused this study on
the laboratory process instead of analyzing differences
among individual banks.
The following variables of the banking process and
disease and transplant characteristics were analyzed: VR
of the CBU before cryopreservation, time interval
between collection of the CBU and transplantation,
recipient’s age at CBT (adult vs. pediatric patients), diag-
nosis (myeloid vs. lymphoid leukemia), disease status at
CBT, intensity of the conditioning regimen (reduced-
intensity conditioning [RIC] vs. myeloablative condition-
ing [MAC] that was defined as regimens containing
either total body irradiation with a dose of >6 Gy or
busulfan with a dose of >6.4 mg/kg intravenous [8 mg/
kg if oral] degree of HLA matching (number of mis-
matched HLA, defined as HLA-A,B by low-resolution
typing and DRB1 high-resolution typing), cryopreserved
TNCs (reported as 107/kg recipient weight), and cyto-
megalovirus (CMV) status of the patient.
The primary endpoint of this study was 100-day
NRM. Secondary endpoints were neutrophil engraftment,
acute and chronic GVHD rate, OS, and leukemia-free sur-
vival (LFS). The review board of Eurocord/EBMTapproved
this study.
Data search
Patients fulfilling the above inclusion criteria were
selected from the Eurocord database. An invitation letter
to participate in the study was sent to the banks that
released CBU for transplant. Eurocord bank data collec-
tion forms were modified to integrate a larger set of labo-
ratory variables. Data already reported to Eurocord were
extracted and included in the updated data forms. All the
banks that agreed to participate in the study received a
form that only reported the selected patients’data. The list
of participating banks is reported in Table S1 (available as
supporting information in the online version of this
paper).
Outcome definitions
The secondary endpoint of the study was neutrophil
recovery, which was defined as achieving absolute neutro-
phil count of at least 0.5 3 109/L for 3 consecutive days.
The diagnosis and grading of acute and chronic GVHD
was assigned by the transplantation center using standard
criteria.18 Relapse and death from any cause were consid-
ered events. NRM was defined as death without prior
relapse. LFS was calculated from the date of CBT until
death, relapse, or last disease-free follow-up. OS was cal-
culated from the date of CBT until death or last observa-
tion alive.
Statistical analysis
The analysis was carried out from October 2013. Median
values and ranges were used for continuous variables and
percentages for categorical variables. Patient, disease and
transplantation characteristics were compared in CBUs
that either underwent or did not undergo VR using the
nonparametric Wilcoxon test for continuous variables and
Pearson’s chi-square test for categorical variables. For
each continuous variable, the study population was ini-
tially divided into quartiles and in two groups by the
median. The median value was found to be the best cutoff
for analysis of outcomes. The probabilities of OS and LFS
were calculated using the Kaplan-Meier method and the
log-rank test for univariate comparisons. The probabilities
of neutrophil engraftment, grade II to IV acute and
chronic GVHD, relapse, and NRM were calculated with
the cumulative incidence estimator using death or relapse
as a competing event. Multivariate analyses were per-
formed using Cox proportional hazards regression model
for LFS and OS and Fine and Gray’s proportional hazards
regression model for other outcomes. Besides VR, we
included in the univariate analysis clinically relevant vari-
ables related to the patient (age at CBT, CMV serostatus),
to the disease (acute lymphoblastic leukemia [ALL] vs.
acute myeloid leukemia [AML] and first CR [CR1] vs. sec-
ond or third CR [CR2/CR3]), to transplantation technique
(date of transplantation, conditioning), and to the graft
(frozen TNC number, HLA matching). Variables that
reached a p value of 0.15 in the univariate analysis were
included in the initial models and variables were elimi-
nated one at a time in a stepwise fashion to keep only the
variables that reached a p value of 0.05 in the final model.
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p values were two-sided. Statistical analyses were per-
formed with computer software (SPSS, SPSS Inc.; SPLUS
MathSoft, Inc.; and R, https://www.r-project.org/).
RESULTS
Patient population
A total of 677 patients transplanted in 133 centers from 47
countries were selected for this analysis. CBU for trans-
plant were provided by 38 banks in Europe, America, and
Australia between 1997 and 2010 (median, 2005). Median
age at CBT was 7.9 years (range, 0.1-68.2 years), with
73.6%/26.4% pediatric/adult ratio. This proportion reflects
the diagnosis distribution: 405 (59.8%) were ALL while 272
(40.2%) were AML. Most patients (83.7%) received a MAC
regimen. Median follow-up for survivors was 49 months
(range, 1.4-168 months).
CBU characteristics
The median interval between CBU collection and trans-
plant was 4.1 years (range, 0.2-16.3 years). Volume at col-
lection (Fig. 1A), including anticoagulant, was
1306 34 mL (mean6 SD), containing a median of 5.86 3
107 TNCs/kg recipient weight (range, 3.02 3 107-29.28 3
107 TNCs/kg). Median frozen volume varied largely, due
to the increasing use of concentrating the graft (Fig. 1B);
overall the median (range) cryopreserved volume was 61
(10-430) mL. DMSO was the cryoprotectant used in all
CBUs included in this analysis; data about the storage
phase were available in 477 CBUs, being in liquid phase in
451 (94.5%) of them.
QCs at release
Control of the CBU identity at release on a reference sam-
ple is considered mandatory in the FACT-NetCord stand-
ards (4th Edition, 2010). A question about QC on cell
viability in thawed CBU-associated samples was included
in this survey and was reported to be carried out in 345
units. The most frequently reported methods included try-
pan blue (30.9%), 7-actinomycin-D (21.2%), and acridine
orange (28.8%). The reported percent viabilities after
thawing (mean6SD) were 79.96 17.2, 62.56 22.8, and
89.56 9, respectively.
TABLE 1. Patients and graft characteristic according to VR of the CBU*
VR
Variable No (n5276) Yes (n5401) p value
Year of transplant 2004 (97-10) 2006 (97-10) <0.0001
Year of CBU collection 1998 (93-07) 2001 (94-10) <0.0001
Recipient age (years) 9.3 (0.09-68.2) 6.8 (0.3-64) 0.004
Adults/children 80/196 98/302 0.23
AML/ALL 107/169 165/236 0.46
CR1 vs. CR2/CR3 167/109 206/195 0.02
RIC/MAC 54/213 53/337 0.03
HLA disparities <2/2 138/132 235/145 0.006
TNC count at freezing (3107/kg) 5.53 (3.03-26.1) 6.03 (3-29.3) 0.04
* Data are reported as median (range) or number.
Fig. 1. (A) Distribution of CBU volume at collection (n5677). (B)
Distribution of CBU volume at freezing (n5589). The bimodal
shape reflects the impact of VR in 58% of the selected CBU.
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VR and outcomes
A VR of the CBU before freezing was reported in 401
(59.2%) of the 677 selected transplants. The procedure
was not routinely applied in the early years of banking;
therefore, transplants carried out with volume-reduced
CBUs have become frequent in more recent years, result-
ing in some differences between the two groups. Table 1
summarizes the characteristics of this subset of patients:
overall, unmanipulated CBUs were used earlier and in
younger patients, containing less TNCs/kg patient’s body
weight, with a better HLA matching and in a more
advanced phase of disease. A further analysis was carried
out in concentrated units (i.e., those with VR), according
to the extent of CBU volume before freezing (30 mL vs.
>30 mL). VR below 30 mL was almost always (97%)
achieved by adding HES as the sedimenting agent.
Results of univariate analysis are showed in Table 2.
VR at any level was not associated with outcomes, either
in univariate or in multivariate analysis (Fig. 2).The 60-
day cumulative incidence of neutrophil engraftment was
876 1%. In multivariate analysis (Table 3), patients receiv-
ing TNCs of at least 5.86 3 107/kg presented a higher
probability of neutrophil engraftment (hazard ratio [HR],
1.57; 95% CI, 1.30-1.88; p< 0.001).
Overall, 100-day cumulative incidence of acute
GVHD and 4-year cumulative incidence of chronic GVHD
were 296 2 and 216 2%, respectively. Transplantation of
CBUs with two or more of six HLA mismatches was asso-
ciated with increased risk of chronic GVHD (HR, 1.70; 95%
CI, 1.05-2.78; p5 0.033; Table 3). Relapse incidence (RI)
was 276 2% at 4 years. Disease status was the only factor
associated with RI in multivariate analysis (Table 3; HR,
0.68; 95% CI, 0.48-0.96; p5 0.030 for patients transplanted
in CR1). NRM was 166 2% at 100 days and 306 2% at 4
years. Diagnosis of AML and CMV-negative serology were
both associated with decreased 100-day NRM in multivar-
iate analysis (Table 3; HR, 0.56; 95% CI, 0.35-0.88;
p5 0.014; and HR, 0.58; 95% CI, 0.38-0.90; p5 0.016,
respectively).
The 4-year OSs in CBTs carried out with either con-
centrated or nonconcentrated CBUs were 466 3 and
436 3%, respectively (p5 0.43; Fig. 2). In multivariate
analysis, factors associated with increased survival (both
OS and LFS) were transplantation in children, in CR1, and
diagnosis of AML (Table 3).
DISCUSSION
This is a large-scale, retrospective registry analysis focus-
ing on the clinical impact of the major variables associ-
ated to the banking of CBUs for allogeneic transplantation
in an unrelated setting: namely, VR and CBU age at thaw-
ing. Such analysis had been previously reported in the
form of internal analysis by the individual CBB.4,19,20 Dif-
ferences in CB banking were also analyzed within single
CBT programs.8
QC programs have been implemented to ensure the
quality of CBUs. FACT (Foundation for Accreditation of
Cellular Therapy)-NetCord and the AABB programs rely
on a list of procedures to be followed by CBBs to provide
bank accreditation through an “on-site” inspection pro-
cess. In some countries, local accreditation systems of the
banks are in place. The accreditation systems aim at
standardizing all the banking steps with the final goal of
achieving better quality and homogeneity in the banks’
CBU inventory, therefore improving the clinical outcomes
of CBT.21 Nevertheless, selection of a CBU from an accred-
ited bank is not currently mandatory. Indeed, it should be
mentioned that most of the major banks have been oper-
ating for 10 years or longer and that their operating proce-
dures may have changed through such an interval,
possibly raising further biases. Therefore, the influence of
banking on the clinical outcome needs to be investigated
through the analysis of all major variables associated with
the banking process, from collection to shipping, rather
than those associated with the CBB itself. In this regard, it
should be noted that the duration of the storage did not
have any negative impact on the clinical outcome. Inter-
estingly, the number of frozen TNCs is higher in volume-
reduced CBUs, due to the more recent attitude of CBBs to
accept only high-quality units for storage.
This large, retrospective study shows that current
methods aimed at reducing the CBU volume before freez-
ing do not affect the clinical outcome of the CBT, therefore
providing evidence of a satisfactory validation and repro-
ducibility of such techniques. Methods are based on the
removal of components of the graft that do not influence
the engraftment and immune recovery, such as plasma
and RBCs. Keeping the latter in the graft (RBC-replete
units) results in a higher frozen volume and probably in a
higher content of PMNs, compared to RBC-depleted units.
In fact, PMNs tend to sediment faster than mononuclear
cells, having a higher probability to be removed together
with the RBC pellet after centrifugation. A correction fac-
tor was proposed for CBUs manipulated by plasma deple-
tion,22 but this approach is still controversial.23 We show
here that the outcome of transplants performed with CBU
containing an adequate number of TNCs at freezing (3
3 107/kg recipient body weight) is not influenced by the
reduction of the graft volume before cryopreservation.
Interestingly, this result was confirmed with any concen-
tration and any method used; we adopted 30 mL to dis-
criminate between RBC-depleted and RBC-replete units,
respectively. A difference in the PMN content is expected
in the two subsets, possibly too small to significantly
influence the engraftment speed when combined with the
other graft- and patient-associated variables.
It must be stressed that results derived by any registry
analysis can be biased and their generalization should be
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validated through prospective studies; however, our data
collected through a large, bank-independent analysis sug-
gest that the cryogenic space saved by a high-fold reduction
of the CBU volume does not have any major negative clini-
cal impact, thus encouraging this increasingly used practice.
As expected, all the selected CBUs were maintained in
liquid nitrogen–based cryogenic systems. The current
standards specifically require that the product is kept at a
temperature lower than 21508C, thus using vapor-phase
storage or mechanical freezers.24 Concerns about the long-
term storage of unrelated, allogeneic CBUs can probably
account for the choice of the liquid phase for both the
lower temperature and the longer maintenance of the opti-
mal storage conditions even in the occurrence of inconven-
iences such as temporary lack of power or nitrogen supply.
The major lack of standardization in the banking pro-
cess was found in the product characterization and espe-
cially in the QC on a reference sample. This is an
important issue also due to the current practice of trans-
plant centers to include cell viability in the CBU selection
process, when different units with similar cellular content
and HLA matching are available for one patient. CD341
cell count at freezing is often lacking in the old units; fur-
thermore, CD341 cell viability assessment in the thawed
sample needs further standardization. Most correlations
between CD341 content and engraftment were generated
at the transplant center level on the thawed product at
infusion,25,26 while the count at freezing was not a better
engraftment predictor than TNCs.27 In this retrospective
analysis the viability of nucleated cells was assessed by
TABLE 3. Multivariate analysis
Multivariate
Variable HR p value
60-day neutrophil engraftment
VR 1.1 0.88
Median year of CBT 1.2 0.12
Age at CBT (adult vs. children) 2.2 0.02
Diagnosis (AML vs. ALL) 1.8 0.62
Remission status at CBT 0.8 0.69
Conditioning (RIC vs. MAC) 0.7 0.45
Number of mismatches 0.3 0.6
TNC at collection 4.8 0.001
Patient CMV status 0.1 0.87
100-day NRM
VR 0.7 0.19
Median year of CBT 0.8 0.37
Age at CBT (adult vs. children) 1.3 0.41
Diagnosis (AML vs. ALL) 0.6 0.014
Remission status at CBT 0.8 0.45
Conditioning (RIC vs. MAC) 1.0 0.83
Number of mismatches 1.0 0.8
TNC at collection 0.8 0.5
Patient CMV status 0.6 0.016
5-year OS
VR 1.0 0.81
Median year of CBT 0.9 0.39
Age at CBT (adult vs. children) 1.6 0.009
Diagnosis (AML vs. ALL) 0.7 0.001
Remission status at CBT 0.7 0.007
Conditioning (RIC vs. MAC) 1.0 0.85
Number of mismatches 1.0 0.81
TNC at collection 1.0 0.95
Patient CMV status 0.8 0.16
A
B
C
Fig. 2. Neutrophil engraftment (A), NRM (B), and OS (C)
according to the VR of the CBU. () Unmanipulated CBU;
(—) volume-reduced CBU.
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different methods: a clear description of the method
should be included on the unit report to enable the trans-
plant center to perform a realistic evaluation of the QC
result in the CBU selection process. Indeed, a cooperative
effort in the bank’s network should be devoted to improve
the standardization of both characterization and QCs of
the units exposed in the registries.
An international network of CBBs, transplant scien-
tific societies, and registries have contributed in the past
20 years to make unrelated CB transplantation a clinical
option for many patients missing a suitable donor. The
current challenge is to improve the quality of the world-
wide inventory by focusing collection of CBUs targeted at
ethnic minorities and larger units. Improving the charac-
terization of the CBUs by further standardization of the
banking process will go a long way in improving outcomes
after transplantation of this graft source. Finally it should
be kept in mind that, apart from the graft quality, other
clinical factors such as age, disease status, and condition-
ing regimen must be considered in the evaluation of CB
as a stem cell source for transplantation.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in
the online version of this article at the publisher’s Web
site:
Table S1. List of cord blood banks contributing to the
study.
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